共查询到20条相似文献,搜索用时 62 毫秒
1.
目的:探讨慢性阻塞性肺疾病急性加重期(AECOPD)的药物治疗方案及临床药师实施药学监护方法.方法:以2013年12月收治的1例AECOPD患者为例,临床药师结合最新的诊治指南,协助医师为AECOPD患者制订治疗方案并实施全程的药学监护.结果:临床药师通过实施药学监护,参与整个治疗过程,及时发现和解决了患者药物治疗的问题,为临床合理用药提供了意见.结论:临床药师对AECOPD患者实施药学监护工作,可以提高药物治疗效果,避免和减少药品不良反应/事件. 相似文献
2.
3.
4.
目的探索临床药师对脑梗死患者的药学监护方案。方法以脑梗死防治指南为依据,根据掌握的药学知识,临床药师对患者在住院期间的用药情况进行全程监护,重点针对药物选择的合理性和药品的不良反应及药物的相互作用,对患者进行具体化药学服务并制定个体化监护计划。结果I临床药师积极参与临床的治疗过程,指导临床用药,可减少药品不良反应及药物配伍禁忌的发生,规范临床合理用药,提高治疗水平。结论临床药师应针对具体患者,开展个体化的药学监护。 相似文献
5.
6.
7.
目的:探讨临床药师参与抗感染治疗与开展药学监护的方法。方法:针对1例开颅术后颅内感染患者,临床药师从药物选择、给药剂量、疗程、不良反应监测等方面,为患者制订个体化治疗方案,并进行药学监护。结果:本次药学监护取得了明显效果,提高了药物治疗水平。结论:临床药师参与抗感染个体化治疗方案的制订、向患者提供药学服务、开展药学监护,可减少或避免药品不良反应的发生,提高药物治疗效果。 相似文献
8.
目的:通过对1例AECOPD老年患者的用药分析,介绍临床药师在常见疾病诊疗过程中发挥的药学作用。方法:对1例老年AECOPD患者用药过程建立药学监护,并进行治疗方案药物分析。结果:通过临床药师的参与,优化治疗方案。结论:临床药师对患者治疗过程建立药学监护,开展用药指导,避免治疗过程药品不良反应的发生。 相似文献
9.
目的 :探讨临床药师对慢性阻塞性肺疾病患者实施药学监护的作用。方法 :临床药师通过临床查房,与医师共同制定个体化治疗方案,建立药历,重点针对药物选择适宜性和药品不良反应以及药物的相互作用,提出合理的药学监护措施及健康教育计划。结果:临床药师为患者实施药学监护可提高药物治疗效果,提高患者的依从性,减少用药风险。结论:临床药师参与临床的治疗过程,可促进临床合理用药,切实保障医疗质量安全。 相似文献
10.
11.
12.
13.
14.
目的:为了使并发肺部感染的病人更多、更好、更早的痊愈。方法:通过对32例颅脑外伤并发肺部感染病人的严密观察,采取更换体位、超声雾化、有效排痰训练等有效的护理措施干预,从而控制了肺部感染。结果:痊愈17例,占53.1%;显效12例,占37.5%,无效2例,占6.2%;死亡1例,占3.1%;实践证明,有效的护理干预对提高患者治疗成功率有着重要意义。 相似文献
15.
1例78岁男性患者因带状疱疹神经痛、慢性阻塞性肺疾病合并感染,给予头孢唑肟钠(2.25 g静脉滴注,1次/d)、卡马西平(0.2 g口服,2次/d)、尼美舒利(100 mg口服,2次/d)、二羟丙茶碱(0.5 g静脉滴注,1次/d)、甲钴胺(0.5 mg口服,3次/d)、地塞米松(5 mg,静脉滴注1次)、盐酸哌替啶(25 mg,肌内注射1次)和盐酸布桂嗪(100 mg,肌内注射3次)等药物治疗。第7天,停用头孢唑肟钠,改为磷霉素钠(8 g静脉滴注,1次/d)。第11天,血常规检查示白细胞计数1.6×10^9/L,中性粒细胞0.03,中性粒细胞绝对值0.1×10^9/L,淋巴细胞绝对值0.9×10^9/L。立即停用所有药物,给予对症支持治疗。第15天,外周血白细胞计数0.9×10^9/L,中性粒细胞0.02,中性粒细胞绝对值0.1×10^9/L,淋巴细胞绝对值0.7×10^9/L。行骨髓穿刺检查,诊断为粒细胞缺乏症。第17天患者出现右肺气胸、肺不张。第20天出现急性呼吸衰竭、多脏器衰竭合并重症感染,经抢救无效死亡。 相似文献
16.
P. Kendrew F. Ward D. Buick D. Wright R. Horne P. Kendrew F. Ward 《The International journal of pharmacy practice》2001,9(Z1):5-5
□ Due to the nature of chronic pain it would be expected that patients are highly adherent to their pain medication. However, results from this study have shown that 23 per cent of patients often or always avoid using their pain medication, 13.4 per cent often or always alter dosages, and 10.3 per cent often or always stop taking their medication for a while. This suggests intentional non‐adherence to pain medication □ Less than 50 per cent of respondents were satisfied with information provided on side effects, what to do if side effects occur, and possible interactions with other medication □ Patients' satisfaction with information about their medication was related to self‐reported adherence; greater satisfaction was associated with higher self‐reported adherence 相似文献
17.
Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation 总被引:1,自引:0,他引:1
Gordon MA Gil J Lu B Zhang W Yang D Yun J Schneider S Groshen S Iqbal S Press OA Rhodes K Lenz HJ 《Pharmacogenomics》2006,7(1):67-88
PURPOSE: Stage II and III adenocarcinoma of the rectum has an overall 5-year survival rate of approximately 50%, and tumor recurrence remains a major problem despite an improvement in local control through chemotherapy and radiation. The efficacy of chemoradiation therapy may be significantly compromised as a result of interindividual variations in clinical response and host toxicity. Therefore, it is imperative to identify those patients who will benefit from chemoradiation therapy and those who will develop recurrent disease. In this study, we tested whether a specific pattern of 21 polymorphisms in 18 genes involved in the critical pathways of cancer progression (i.e., drug metabolism, tumor microenvironment, cell cycle regulation, and DNA repair) will predict the risk of tumor recurrence in rectal cancer patients treated with chemoradiation. PATIENTS AND METHODS: A total of 90 patients with Stage II or III rectal cancer treated with chemoradiation were genotyped using polymerase chain reaction (PCR)-based techniques for 21 polymorphisms. RESULTS: A polymorphism in interleukin (IL)-8 was individually associated with risk of recurrence. Classification and regression tree analysis of all polymorphisms and clinical variables developed a risk tree including the following variables: node status, IL-8, intracellular adhesion molecule-1, transforming growth factor-beta, and fibroblast growth factor receptor 4. CONCLUSION: Genomic profiling may help to identify patients who are at high risk for developing tumor recurrence, and those who are more likely to benefit from chemoradiation therapy. A larger prospective study is needed to validate these preliminary data using germline polymorphisms on tumor recurrences in rectal cancer patients treated with chemoradiation. 相似文献
18.
19.
20.
目的 对类风湿关节炎合并肺间质纤维化患者的临床特征进行分析,为今后的临床诊治工作提供可靠的参考依据.方法 选取2010年1月-2013年3月我院收治的类风湿性关节炎患者102例,按照是否合并肺间质纤维化分成合并组和单纯组,而后对这两组的临床观察指标进行对比分析.结果 合并组患者的男性所占比例、吸烟者比例、患者年龄、发病年龄、抗环瓜氨酸抗体、类风湿因子、C反应蛋白水平以及骨破坏发生率均较单纯组高.结论 类风湿关节炎患者合并肺间质纤维化可能与诸多临床指标均存在较大的相关性,临床应给予关注,采取有效措施进行预防和治疗. 相似文献